Sedation Therapeutics
1. Byfavo patent expiration
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10195210 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(5 years from now) | |
| US10342800 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(5 years from now) | |
| US10472365 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(1 year, 5 months from now) | |
| US9827251 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Jan, 2034
(8 years from now) | |
| US9737547 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(5 years from now) | |
| US10052334 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(5 years from now) | |
| US10961250 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(1 year, 5 months from now) | |
| US9561236 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Apr, 2033
(7 years from now) | |
| US10722522 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(5 years from now) | |
| US9777007 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(1 year, 5 months from now) | |
| US9914738 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2025 |
Drugs and Companies using REMIMAZOLAM BESYLATE ingredient
NCE-1 date: 06 October, 2024
Market Authorisation Date: 06 October, 2020
Dosage: POWDER
More Information on Dosage
BYFAVO family patents
2. Lusedra patent expiration
Treatment: Sedative-hypnotic agent indicated for monitored anesthesia care (mac) sedation
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6204257 | EISAI INC | Water soluble prodrugs of hindered alcohols |
Jul, 2022
(3 years ago) | |
| US6872838 | EISAI INC | Water soluble prodrugs of hindered alcohols |
Aug, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2013 |
Drugs and Companies using FOSPROPOFOL DISODIUM ingredient
NCE-1 date: 12 December, 2012
Market Authorisation Date: 12 December, 2008
Dosage: SOLUTION
More Information on Dosage
LUSEDRA family patents
3. Precedex patent
expiration
Treatment: Intensive care unit sedation; Use for sedation
PRECEDEX's oppositions filed in EPO
PRECEDEX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4910214 (Pediatric) | HOSPIRA | Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist |
Jan, 2014
(11 years ago) | |
| US6716867 | HOSPIRA | Use of dexmedetomidine for ICU sedation |
Mar, 2019
(6 years ago) | |
| US4910214 | HOSPIRA | Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist |
Jul, 2013
(12 years ago) | |
|
US6716867 (Pediatric) | HOSPIRA | Use of dexmedetomidine for ICU sedation |
Oct, 2019
(6 years ago) | |
| US8455527 | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jan, 2032
(5 years from now) | |
| US9616049 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(5 years from now) | |
| US8242158 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(5 years from now) | |
| US10016396 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(5 years from now) | |
| US8338470 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(5 years from now) | |
| US8648106 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(5 years from now) | |
| US9320712 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(5 years from now) | |
|
US8455527 (Pediatric) | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jul, 2032
(6 years from now) | |
|
US8242158 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(6 years from now) | |
|
US8338470 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(6 years from now) | |
|
US8648106 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(6 years from now) | |
|
US9320712 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(6 years from now) | |
|
US9616049 (Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-577) | Oct 17, 2011 |
| M(M-61) | Jun 17, 2016 |
| Pediatric Exclusivity(PED) | Dec 17, 2016 |
| New Patient Population(NPP) | Dec 16, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 31 January, 2020
Dosage: INJECTABLE
How can I launch a generic of PRECEDEX before it's drug patent expiration?
More Information on Dosage
PRECEDEX family patents